A031501 – Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation.
1. WHAT TYPE OF CANCER? WHAT STAGE?
Urothelial cancers (Bladder, Ureter, or Kidney).
2. WHO IS ELIGIBLE?
Patients who have had complete resection (TURBT that completely removed tumor is okay).
3. HOW WILL I BE TREATED?
The study looks at treating with Pembrolizumab, an anti-PD-1 immunotherapy.
For Physicians: More information about this specific trial at clinicaltrials.gov